BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/23/2022 10:13:16 AM | Browse: 356 | Download: 996
 |
Received |
|
2022-06-24 17:30 |
|
Peer-Review Started |
|
2022-06-24 17:33 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-08-06 06:52 |
|
Revised |
|
2022-08-16 20:42 |
|
Second Decision |
|
2022-09-05 03:24 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-09-06 17:14 |
|
Articles in Press |
|
2022-09-06 17:14 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-09-15 08:44 |
|
Publish the Manuscript Online |
|
2022-09-23 10:13 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Liver-specific drug delivery platforms: Applications for the treatment of alcohol-associated liver disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jeffrey Barr Warner, Steven Corrigan Guenthner, Josiah Everett Hardesty, Craig James McClain, Dennis Ray Warner and Irina Andreyevna Kirpich |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Institutes of Health |
R01AA028905-01A1 |
| National Institutes of Health |
U01AA026934 |
| National Institutes of Health |
1F31AA028423-01A1 |
| National Institutes of Health |
F32AA027950-01A1 |
| National Institute of General Medical Sciences of the National Institutes of Health |
P20GM113226 |
| National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health |
P50AA024337 |
|
| Corresponding Author |
Irina Andreyevna Kirpich, N/A, PhD, Associate Professor, Department of Microbiology and Immunology, University of Louisville School of Medicine, 505 S. Hancock St., Louisville, KY 40202, United States. irina.kirpich@louisville.edu |
| Key Words |
Liver targeted delivery; Nanoparticles; Liposomes; Polymeric nanoparticles; Precision medicine; Alcohol associated liver disease |
| Core Tip |
Alcohol-associated liver disease (ALD) is a common chronic liver disease and global healthcare burden. While a great deal of pre-clinical research attention is paid to ALD, many experimental therapeutics which are administered systemically suffer from poor pharmacokinetics or poor efficacy. Liver-targeted delivery may address these drawbacks while avoiding extra-hepatic side effects. This article reviews literature applying liver-targeted drug delivery platforms such as liposomes, exosomes, polymeric nanoparticles, viruses, and bioengineered bacteria to the treatment of ALD. |
| Publish Date |
2022-09-23 10:13 |
| Citation |
Warner JB, Guenthner SC, Hardesty JE, McClain CJ, Warner DR, Kirpich IA. Liver-specific drug delivery platforms: Applications for the treatment of alcohol-associated liver disease. World J Gastroenterol 2022; 28(36): 5280-5299 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i36/5280.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i36.5280 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
